The PXR rs7643645 polymorphism is associated with the risk of higher prostate-specific antigen levels in prostate cancer patients

PLoS ONE

Volumn 9, Issue 6, 2014, Pages

  Reyes Hernández, Octavio D ^a   Vega, Libia ^b   Jiménez Ríos, Miguel A ^c   Martínez Cervera, Pedro F ^c   Lugo García, Juan A ^a   Hernández Cadena, Leticia ^d   Ostrosky Wegman, Patricia ^e   Orozco, Lorena ^f   Elizondo, Guillermo ^b  

^a HOSPITAL JUÁREZ DE MÉXICO   (Mexico)

^b DEPARTAMENTO DE FÍSICA   (Mexico)

^c INSTITUTO NACIONAL DE CANCEROLOGÍA   (Mexico)

^d INSTITUTO NACIONAL DE SALUD PÚBLICA   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f INSTITUTO NACIONAL DE MEDICINA GENÓMICA   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 3A4; PREGNANE X RECEPTOR; PROSTATE SPECIFIC ANTIGEN; CYTOCHROME P450 3A; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; STEROID RECEPTOR;

AGED; ANTIGEN DETECTION; ARTICLE; CANCER GRADING; CASE CONTROL STUDY; CONTROLLED STUDY; CYP3A4 GENE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLEASON SCORE; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; ONCOGENE; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; ALLELE; BLOOD; GENE EXPRESSION REGULATION; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROSTATE TUMOR; RISK FACTOR; SINGLE NUCLEOTIDE POLYMORPHISM; UPREGULATION;

AGED; ALLELES; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP3A; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KALLIKREINS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RECEPTORS, STEROID; RISK FACTORS; UP-REGULATION;

EID: 84903377307     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0099974     Document Type: Article

References (37)

1. Bostwick DG, Burke HB, Djakiew D, Euling S, Ho SM, et al. (2004) Human prostate cancer risk factors. Cancer 101: 2371-2490. (Pubitemid 39505434)
2. Hsing AW, Chokkalingam AP (2006) Prostate cancer epidemiology. Front Biosci 11: 1388-1413. (Pubitemid 43253429)
3. Hsing AW (1996) Hormones and prostate cancer: where do we go from here? J Natl Cancer Inst 88: 1093-1095.
4. Hsing AW, Chu LW, Stanczyk FZ (2008) Androgen and prostate cancer: is the hypothesis dead? Cancer Epidemiol Biomarkers Prev 17: 2525-2530.
5. Balk SP, Knudsen KE (2008) AR, the cell cycle, and prostate cancer. Nucl Recept Signal 6: e001.
6. Zanger UM, Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther 138: 103-141.
7. Waxman DJ, Attisano C, Guengerich FP, Lapenson DP (1988) Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6 beta-hydroxylase cytochrome P-450 enzyme. Arch Biochem Biophys 263: 424-436.
8. Sundin M, Warner M, Haaparanta T, Gustafsson JA (1987) Isolation and catalytic activity of cytochrome P-450 from ventral prostate of control rats. J Biol Chem 262: 12293-12297.
9. Brian WR, Sari MA, Iwasaki M, Shimada T, Kaminsky LS, et al. (1990) Catalytic activities of human liver cytochrome P-450 IIIA4 expressed in Saccharomyces cerevisiae. Biochemistry 29: 11280-11292.
10. Fujimura T, Takahashi S, Urano T, Kumagai J, Murata T, et al. (2009) Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer. Urology 74: 391-397.
11. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP (1994) Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270: 414-423. (Pubitemid 24229655)
12. Thummel KE, Shen DD, Podoll TD, Kunze KL, Trager WF, et al. (1994) Use of midazolam as a human cytochrome P450 3A probe: II. Characterization of inter- and intraindividual hepatic CYP3A variability after liver transplantation. J Pharmacol Exp Ther 271: 557-566. (Pubitemid 24333174)
13. Ozdemir V, Kalow W, Tang BK, Paterson AD, Walker SE, et al. (2000) Evaluation of the genetic component of variability in CYP3A4 activity: a repeated drug administration method. Pharmacogenetics 10: 373-388. (Pubitemid 30433571)
14. Rebbeck TR, Jaffe JM, Walker AH, Wein AJ, Malkowicz SB (1998) Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J Natl Cancer Inst 90: 1225-1229. (Pubitemid 28407089)
15. Paris PL, Kupelian PA, Hall JM, Williams TL, Levin H, et al. (1999) Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients. Cancer Epidemiol Biomarkers Prev 8: 901-905. (Pubitemid 29508726)
16. Kittles RA, Chen W, Panguluri RK, Ahaghotu C, Jackson A, et al. (2002) CYP3A4-V and prostate cancer in African Americans: causal or confounding association because of population stratification? Hum Genet 110: 553-560. (Pubitemid 36075004)
17. Taioli E, Sears V, Watson A, Flores-Obando RE, Jackson MD, et al. (2013) Polymorphisms in CYP17 and CYP3A4 and prostate cancer in men of African descent. Prostate 73: 668-676.
18. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, et al. (2001) Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27: 383-391. (Pubitemid 32268418)
19. Wandel C, Witte JS, Hall JM, Stein CM, Wood AJ, et al. (2000) CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68: 82-91. (Pubitemid 30609830)
20. Kliewer SA, Moore JT, Wade L, Staudinger JL, Watson MA, et al. (1998) An orphan nuclear receptor activated by pregnanes defines a novel steroid signaling pathway. Cell 92: 73-82. (Pubitemid 28053299)
21. Hustert E, Zibat A, Presecan-Siedel E, Eiselt R, Mueller R, et al. (2001) Natural protein variants of pregnane X receptor with altered transactivation activity toward CYP3A4. Drug Metab Dispos 29: 1454-1459. (Pubitemid 33000692)
22. Schroder FH, Hermanek P, Denis L, Fair WR, Gospodarowicz MK, et al. (1992) The TNM classification of prostate cancer. Prostate Suppl 4: 129-138.
23. Kraft P, Wacholder S, Cornelis MC, Hu FB, Hayes RB, et al. (2009) Beyond odds ratios - communicating disease risk based on genetic profiles. Nat Rev Genet 10: 264-269.
24. Zeigler-Johnson CM, Walker AH, Mancke B, Spangler E, Jalloh M, et al. (2002) Ethnic differences in the frequency of prostate cancer susceptibility alleles at SRD5A2 and CYP3A4. Hum Hered 54: 13-21. (Pubitemid 35404245)
25. Tayeb MT, Clark C, Sharp L, Haites NE, Rooney PH, et al. (2002) CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia. Oncol Rep 9: 653-655.
26. Amirimani B, Ning B, Deitz AC, Weber BL, Kadlubar FF, et al. (2003) Increased transcriptional activity of the CYP3A4*1B promoter variant. Environ Mol Mutagen 42: 299-305. (Pubitemid 38054375)
27. Spurdle AB, Goodwin B, Hodgson E, Hopper JL, Chen X, et al. (2002) The CYP3A4*1B polymorphism has no functional significance and is not associated with risk of breast or ovarian cancer. Pharmacogenetics 12: 355-366. (Pubitemid 34816415)
28. Lamba JK, Lin YS, Thummel K, Daly A, Watkins PB, et al. (2002) Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12: 121-132. (Pubitemid 34298916)
29. Ball SE, Scatina J, Kao J, Ferron GM, Fruncillo R, et al. (1999) Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 66: 288-294. (Pubitemid 29451761)
30. Lamba J, Lamba V, Strom S, Venkataramanan R, Schuetz E (2008) Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression. Drug Metab Dispos 36: 169-181.
31. Fujimura T, Takahashi S, Urano T, Tanaka T, Zhang W, et al. (2012) Clinical significance of steroid and xenobiotic receptor and its targeted gene CYP3A4 in human prostate cancer. Cancer Sci 103: 176-180.
32. Johnson JL, Ellis BA, Noack D, Seabra MC, Catz SD (2005) The Rab27a-binding protein, JFC1, regulates androgen-dependent secretion of prostatespecific antigen and prostatic-specific acid phosphatase. Biochem J 391: 699-710. (Pubitemid 41634797)
33. Young CY, Montgomery BT, Andrews PE, Qui SD, Bilhartz DL, et al. (1991) Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res 51: 3748-3752.
34. Lin MF, Garcia-Arenas R, Chao YC, Lai MM, Patel PC, et al. (1993) Regulation of prostatic acid phosphatase expression and secretion by androgen in LNCaP human prostate carcinoma cells. Arch Biochem Biophys 300: 384-390. (Pubitemid 23225761)
35. Webber MM, Waghray A, Bello D (1995) Prostate-specific antigen, a serine protease, facilitates human prostate cancer cell invasion. Clin Cancer Res 1: 1089-1094.
36. Gray MA, Squires EJ (2013) Effects of nuclear receptor transactivation on boar taint metabolism and gene expression in porcine hepatocytes. J Steroid Biochem Mol Biol 133: 110-119.
37. Konno Y, Kodama S, Moore R, Kamiya N, Negishi M (2009) Nuclear xenobiotic receptor pregnane X receptor locks corepressor silencing mediator for retinoid and thyroid hormone receptors (SMRT) onto the CYP24A1 promoter to attenuate vitamin D3 activation. Mol Pharmacol 75: 265-271.